We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-7.53%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$319M
AUM Growth
-$42M
Cap. Flow
-$13.7M
Cap. Flow %
-4.3%
Top 10 Hldgs %
40.4%
Holding
86
New
14
Increased
23
Reduced
18
Closed
23

Top Buys

1
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M
2
BHVN icon
Biohaven
BHVN
+$8.11M
3
CGON icon
CG Oncology
CGON
+$6.41M
4
KRRO icon
Korro Bio
KRRO
+$5.53M
5
SYRE icon
Spyre Therapeutics
SYRE
+$5.07M

Top Sells

1
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
2
JBIO
Jade Biosciences
JBIO
+$6.65M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.92M
4
TGTX icon
TG Therapeutics
TGTX
+$5.19M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.44M

Sector Composition

1 Healthcare 89.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
76
Larimar Therapeutics
LRMR
$384M
– –
-210,603
Closed -$1.6M
MDGL icon
77
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-6,500
Closed -$1.74M
NTRA icon
78
Natera
NTRA
$38.9B
– –
-25,000
Closed -$2.29M
PTGX icon
79
Protagonist Therapeutics
PTGX
$9.06B
– –
-75,000
Closed -$2.17M
QURE icon
80
uniQure
QURE
$2.77B
– –
-165,000
Closed -$858K
RARE icon
81
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-20,000
Closed -$934K
VKTX icon
82
CALL
Viking Therapeutics
VKTX
$4.31B
– –
-80,000
Closed -$6.56M
XBI icon
83
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-250,000
Closed -$23.7M
ITCI
84
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-50,000
Closed -$3.46M
DCPH
85
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-176,513
Closed -$2.78M
MRNS
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-285,000
Closed -$2.58M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ghost Tree Capital held 86 positions worth $319M, down 12% from $361M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital withdrew a net $13.7M in Q2 2024, closing 23 positions and reducing 18 holdings. Its most notable exit was Jade Biosciences, an estimated $6.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Ascendis Pharma A/S worth $11.8M.

  • Ghost Tree Capital's largest Q2 2024 buy was Ascendis Pharma A/S: 86,721 shares worth $11.8M.
  • Ghost Tree Capital added most to Biohaven in Q2 2024, an estimated $8.11M increase.
  • Ghost Tree Capital's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $8.99M.
  • Ghost Tree Capital fully exited Jade Biosciences in Q2 2024, selling an estimated $6.65M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $319M portfolio in Q2 2024.
  • Ghost Tree Capital opened 14 new positions and closed 23 in Q2 2024.
  • Ghost Tree Capital's portfolio value fell 12% quarter-over-quarter to $319M.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.